Cardiovascular Profile of Modern Sulfonylureas: Focus on Glimepiride

Abstract

Cardiovascular risk has been found to be frequently associated with people with diabetes. The presence of such a condition necessitates the use of caution while prescribing antidiabetic medications to these patients. This is because there has been some concern of antidiabetic drugs and their associated with increase in cardiovascular risk. In this context, glimepiride is a well-studied, efficacious, cost effective option for people with diabetes including those at increased cardiovascular risk. Several clinical studies have validated the ‘cardio-safe’ profile of glimepiride, thereby, rendering it suitable for use in a wide range of people with diabetes. Here we will discuss about the cardiovascular profile of glimepiride and its cardiovascular safety from the cardiovascular outcome trials.